Abstract:Dietary compounds that possess the properties of altering epigenetic processes are gaining popularity as targets for cancer prevention studies. These compounds when administered at optimal concentrations and especially in combination can have enhanced effects in cancer prevention or therapy. It is important to study the interaction of two or more compounds in order to assess their role in enhancing prevention. Genistein (GEN), found in soy, has been extensively studied for its role as an epigenetic modifier especially as a DNA methyltransferase (DNMT) inhibitor and sulforaphane (SFN), found in cruciferous vegetables, is known as a histone deacetylase (HDAC) inhibitor. However, very little is known about the effects of these two compounds in conjunction in breast cancer prevention or therapy. In our current study, we determined that, at certain doses, the compounds have synergistic effects in decreasing cellular viability of breast cancer cell lines. Our results indicate that the combination of GEN and SFN is much more effective than their single doses in increasing the rate of apoptosis and lowering the colony forming potential of these cells. We determined that these compounds inhibit cell cycle progression to G2 phase in MDA-MB-231 and G1 phase in MCF-7 breast cancer cell lines. Additionally, we determined that the combination is effective as an HDAC and histone methyltransferase (HMT) inhibitor. Furthermore, we demonstrated that this combination downregulates the levels of HDAC2 and HDAC3 both at the mRNA and protein levels. We also found that these compounds have the potential to downregulate KLF4 levels, which plays an important role in stem cell formation. The combination of GEN and SFN is also effective in downregulating hTERT levels, which is known to be activated when KLF4 binds to its promoter region. Our hypothesis is further strengthened by in vivo studies, where the combination is administered to transgenic mice in the form of genistein and SFN-enriched broccoli sprouts. We have demonstrated that the combination is more effective in preventing or treating mammary cancer via extending tumor latency and reducing tumor volumes/sizes than either of these dietary components administered alone. These results are consistent with our in vitro study suggesting potential preventive and therapeutic effects of this novel dietary combinatorial approach against breast cancer.

Genistein and Its Synthetic Analogs As Anticancer Agents

Biosynthesis and Anticancer Activity of Genistein Glycoside Derivatives

Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances

Genistein: A promising phytoconstituent with reference to its bioactivities

Unleashing the potential of Genistein and its derivatives as effective therapeutic agents for breast cancer treatment

Cellular and molecular mechanisms of genistein in prevention and treatment of diseases: An overview

Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects

Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits

[Genistein Exerts Multiple Suppressive Effects on Human Breast Carcinoma Cells].

Synthesis And Cytotoxic Evaluation Of A Series Of Genistein Derivatives

Genistein as a regulator of signaling pathways and microRNAs in different types of cancers

Genistein: Dual Role in Women’s Health

Molecular Pathways of Genistein Activity in Breast Cancer Cells

Resveratrol and its analogues: promising antitumor agents.

Genistein as Potential Therapeutic Candidate for Menopausal Symptoms and Other Related Diseases

Genistein Mediated Molecular Pharmacology, Cell-Specific Anti-Breast Cancer Mechanism with Synergistic Effect and in silico Safety Measurement

The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation

Therapeutic Potential of Genistein: Preclinical Studies, Clinical Evidence, and Nanotechnology Application

Synthesis and Cytotoxic Evaluation of Novel 7‐o‐modified Genistein Derivatives

Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines

An Updated Review Summarizing the Pharmaceutical Efficacy of Genistein and its Nanoformulations in Ovarian Carcinoma